Methods of preparing dendritic cells with flt3-ligand and...

Details Methods of preparing dendritic cells with flt3-ligand and... Methods of preparing dendritic cells with flt3-ligand and...

2006-12-19

2006-12-19

Gambel, Phillip (Department: 1644)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Method of regulating cell metabolism or physiology

C435S002000, C435S325000, C435S375000

Reexamination Certificate

active

07150992

ABSTRACT:
Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants. When flt3-L is used and/or administered in combination with other reactive agents, e.g. CD40 binding proteins and 4-1BBL or antibodies reactive with 4-1BB, the combination further enhances immune responses and the effectiveness of vaccine adjuvants.

REFERENCES:
patent: 4745099 (1988-05-01), Akamatsu et al.
patent: 5013824 (1991-05-01), Abrams et al.
patent: 5057420 (1991-10-01), Massey
patent: 5061620 (1991-10-01), Tsukamoto et al.
patent: 5114710 (1992-05-01), Takaku et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5185438 (1993-02-01), Lemischka
patent: 5192553 (1993-03-01), Boyse et al.
patent: 5199942 (1993-04-01), Gillis
patent: 5270458 (1993-12-01), Lemischka
patent: 5283354 (1994-02-01), Lemischka
patent: 5326558 (1994-07-01), Turner et al.
patent: 5367057 (1994-11-01), Lemischka
patent: 5397706 (1995-03-01), Correa et al.
patent: 5399493 (1995-03-01), Emerson et al.
patent: 5437994 (1995-08-01), Emerson et al.
patent: 5453357 (1995-09-01), Hogan
patent: 5459069 (1995-10-01), Palsson et al.
patent: 5525708 (1996-06-01), Nocka et al.
patent: 5548065 (1996-08-01), Lemischka
patent: 5554512 (1996-09-01), Lyman et al.
patent: 5627025 (1997-05-01), Steinman et al.
patent: 5635388 (1997-06-01), Bennett et al.
patent: 5843423 (1998-12-01), Lyman et al.
patent: 5914108 (1999-06-01), Tsukamoto et al.
patent: 5994126 (1999-11-01), Steinman et al.
patent: 6015554 (2000-01-01), Galy et al.
patent: 2163105 (1994-05-01), None
patent: 0 563 485 (1992-03-01), None
patent: 0 627 487 (1994-05-01), None
patent: WO 92/18615 (1992-10-01), None
patent: WO 93/08268 (1993-04-01), None
patent: WO 93/20186 (1993-10-01), None
patent: WO 94/26891 (1994-11-01), None
patent: WO 94/28391 (1994-12-01), None
patent: WO 95/00554 (1995-01-01), None
patent: WO 96/00779 (1996-01-01), None
Stanley, E. R. et al., “CSF-1-A Mononuclear Phagocyte Lineage-Specific Hemopoietic Growth Factor,”J. Cell. Bio. 21:151-159, 1983.
Y. Yarden and A. Ullrich, “Growth Factor Receptor Tyrosine Kinases,”Ann. Rev. Biochem. 57:443-478, 1988.
J. G. Flanagan and P. Leder, “The kit Ligand: A Cell Surface Molecule Altered in Steel Mutant Fibroblasts,”Cell 63:185-194, 1990.
D. Cadena and G. Gill, “Receptor tyrosine kinases,”FASEB 6:2332-2337, 1992.
Matthews, W. et al., “A Receptor Tyrosine Kinase Specific to Hematopoietic Stem and Progenitor Cell-Enriched Populations,”Cell 65:1143-1152, 1991.
Lyman, S. D. et al., “Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene,”Oncogene 8:815-822, 1993.
Rosnet, O. et al., “Isolation and Chromosomal Localization of a Novel FMS-like Tyrosine Kinase Gene,”Genomics 9:380-385, 1991.
Lyman, Stewart D. et al., “Molecular Cloning of a Ligand for the flt3/flk-2 Tyrosine Kinase Receptor: A Proliferative Factor for Primitive Hematopoietic Cells,”Cell 75:1157-1167, 1993.
Maroc, N. et al., “Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase,”Oncogene 8:909-918, 1993.
Birg, F. et al., “Expression of theFMS/KIT-Like GeneFLT3in Human Acute Leukemias of the Myeloid and Lymphoid Lineages,”Blood 80(10):2584-2593, 1992.
Dosil, M. et al, “Mitogenic Signalling and Substrate Specificity of the Flk2/Flt3 Receptor Tyrosine Kinase in Fibroblasts and Interleukin 3-Dependent Hematopoietic Cells,”Mol. And Cell. Biol. 13(10):6572-6585 1993.
Hannum, C. et al., “Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs,”Nature 368:643-648, 1994.
Broxmeyer, H. E. et al., “Commentary: A Rapid Proliferation Assay for Unknown Co-Stimulating Factors in Cord Blood Plasma Possibly Involved in Enhancement of In Vitro Expansion and Replating Capacity of Human Hematopoietic Stem/Progenitor Cells,”Blood Cells 20:492-497, 1994.
de Vries, P. et al., “The Effect of the FLT3 Ligand On Purified Murine Pluripotent Hematopoietic Stem Cells,”J. of Cell. Biochem. Suppl. 18b:177, abstract #H110, 1994.
Rossner, M. T. et al., “Fms-like Tyrosine Kinase 3 Catalytic Domain Can Transduce a Proliferative Signal in FDC-P1 Cells That is Qualitatively Similar to the Signal Delivered by c-Fms1,” Cell Growth&Differentiation 5:549-555, 1994.
Small. D. et al., “STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+human bone marrow cells and is involved in the proliferation of early progenitor of early progenitor/stem cells,”Proc. Natl. Acad. Sci. USA 91:459-463, 1994.
Zeigler, F. C. et al., “Cellular and Molecular Characterization of the Role of the FLK-2/FLT-3 Receptor Tyrosine Kinase in Hematopoietic Stem Cells,”Blood 84(8):2422-2430, 1994.
de Vries, P. et al., “The Role of FLT3 Ligand in Early Murine Hematopoiesis,”Blood 84(10) Suppl. I:279a, abstract #1100, 1994.
de Vries, P. et al., “The Effects of Soluble FLT3 Ligand On Murine Pluripotent Hematopoietic Stem Cells,”Experimental Hematology 22(8):724, abstract #174, 1994.
Stewart, F. M. et al., “Post-5-Fluorouracil Human Marrow: Stem Cell Characteristics and Renewal Properties After Autologous Marrow Transplantation,”Blood 81(9):2283-2289, 1993.
Bernhard, H. et al., “Generation of Immunostimulatory Dendritic Cells from Human CD34+Hematopoietic Progenitor Cells of the Bone Marrow and Peripheral Blood,”Cancer Res. 55:1099-1104, 1995.
Chatterjee, M. et al., “Idiotypic antibody immunotherapy of cancer,”Cancer Immunol. Immunotherap. 38:75-82. 1994.
Boon, T., “Toward a Genetic Analysis of Tumor Rejection Antigens,”Adv. Cancer Res. 58:177-211, 1992.
McBride, G., “New Molecule Under Study: Flt3 Ligand May Mobilize Dendritic Cells,”J. Nat'l Cancer Inst. 89(17):1257, 1997.
Pulendran, B. et al., “Developmental Pathways of Dendritic Cells in Vivo: Distinct Function, Phenotype, and Localization of Dendritic Cell Subsets in FLT3 Ligand-Treated Mice,”J. Immunol. 159(5):2222-2231, 1997.
Shurin, M. et al., “FLT3 Ligand Induces the Generation of Functionally Active Dendritic Cells in Mice,”Cell. Immunol. 179(2):174-184, 1997.
Chen, K. et al., “Antitumor Activity and Immunotherapeutic Properties of Flt3-Ligand in a Murine Breast Cancer Model,”Cancer Res. 57(16):3511-3516, 1997.
Strobl, H. et al., “flt3 Ligand in Cooperation with Transforming Growth Factor-β1 Potentiates In Vitro Development of Langerhans-Type Dendritic Cells and Allows Single-Cell Dendritic Cell Cluster Formation Under Serum-Free Conditions,”Blood, 90(4):1425-1434, 1997.
Juan, T. et al., “Chronic Expression of Murine flt3 Ligand in Mice Results in Increased Circulating White Blood Cell Levels and Abnormal Cellular Infiltrates Associated With Splenic Fibrosis,”Blood 90(1):76-84, 1997.
Lynch, D. et al., “Flt3 ligand induces tumor regression and antitumor immune responsesin vivo,” Nature Med. 3(6):625-631, 1997.
Saunders, D. et al., “Dendritic Cell Development in Culture from ThymicPprecursor Cells in the Absence of Granulocyte/Macrophage Colony-stimulating Factor,”J. Exp. Med. 184:2185-2196, 1996.
Maraskovsky, E. et al., “Dramatic Increase in the Numbers of Functionally Mature Dendritic Cells in Flt3 Ligand-treated Mice: Multiple Dendritic Cell Subpopulations Identified,”J. Exp. Med. 184:1953-1962, 1996.
E. Sprecher and Y. Becker, “Role of Langerhans cells and other dendritic cells in viral diseases,”Arch. Virol. 132:1-28, 1993.
Broxmeyer, H. et al., “Flt

Affiliated with

Also associated with

Rating

Methods of preparing dendritic cells with flt3-ligand and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of preparing dendritic cells with flt3-ligand and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of preparing dendritic cells with flt3-ligand and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3677574